Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis

Additional Information

Published Date Dec 19, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3996
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Apoptosis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis.

    To find out more about Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part III: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part III: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

This Report Includes the Following Companies:
A&G Pharmaceutical
Abbott
Access
Active Biotech
Adherex
Advanced Life Sciences
Advanomics
Advantagene
AEgera
AEterna Zentaris
Affimed Therapeutics
Agennix
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
AngioChem
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apotex
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Axelar
Basilea Pharmaceutica
Bayer
Benitec
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biocompatibles
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
BioNumerik
BioSante
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Can-Fite BioPharma
CanBas
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
ChemoCentryx
Chemokine Therapeutics
Chlorogen
Chong Kun Dang
Choongwae
Chroma Therapeutics
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
CLL Pharma
CombinatoRx
Coronado Biosciences
Cosmo Pharmaceuticals
Critical Outcome Technologies
CuraGen
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Dong-A
Dynavax Technologies
ECI
EGEN Inc
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endocyte
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Erimos
Etubics
Exelixis
FasTrack Pharmaceuticals
Fresenius
Galapagos
Gemin X Biotechnologies
Genmab
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlobeImmune
GlycoGenesys
Glycotope
GPC Biotech
Gradalis
Green Cross
Hanmi
Harbor BioSciences
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IkerChem
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intezyne Technologies
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
Kalypsys
Keryx Biopharmaceuticals
Kiadis
Kyowa Hakko Kirin
Labopharm
Leo
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
Mitsubishi Tanabe Pharma
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NewSouth Innovations
NicOx
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
Nycomed Pharma
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pfizer
Pharmaclon
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Plexxikon
POZEN
Pro-Pharmaceuticals
Progen Pharmaceuticals
ProMetic Life Sciences
Protherics
QLT
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rosetta Genomics
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Spirogen
SRI International
SuperGen
Supratek Pharma
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
SynDevRx
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targepeutics
Tau Therapeutics
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
Theryte
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
UMN Pharma
Valeant
ValiRx
Vaxon Biotech
VaxOnco
VBL Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
VM Discovery
Wyeth
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
131I-tositumomab
AEG-35156
afatinib
aflibercept
alvocidib
AME-133
amrubicin hydrochloride
Angiozyme
APG-101
ARQ-197
AS-101
AS-1411
astuprotimut-r
bardoxolone methyl
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
BIBF-1120
bortezomib
bosutinib
brivanib alaninate
BZL-101
canfosfamide hydrochloride
capecitabine
catumaxomab
cediranib
celecoxib
cenersen
cetuximab
cintredekin besudotox
conatumumab
crizotinib
crolibulin
dacomitinib
dinaciclib
docetaxel
doxifluridine
dulanermin
emepepimut-S
endostatin
enzastaurin hydrochloride
erlotinib
etoposide (1)
etoposide phosphate
everolimus
fosbretabulin tromethamine
gataparsen
gefitinib
GT-111
HE-3235
ibritumomab tiuxetan
icotinib hydrochloride
idronoxil
imatinib mesilate
imetelstat
iniparib
interferon (gamma1b)
interferon gamma
irinotecan bead
irinotecan hydrochloride
kahalalide F
lapatinib ditosylate
lestaurtinib
litronesib
lonaprisan
lumiliximab
mapatumumab
MGN-1703
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
nadroparin
navitoclax
necitumumab
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
ON-01910
Oncohist
paclitaxel
paclitaxel polyglumex
panitumumab
panobinostat
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
pemetrexed disodium
perifosine
plitidepsin
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
raltitrexed
ramucirumab
regorafenib
retaspimycin
sagopilone
seliciclib
sorafenib tosylate
SPC-2996
ß-lapachone
SU-6668
talactoferrin alfa
tegafur + uracil
tegafur + uracil + leucovorin
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
topotecan
triciribine phosphate
TRU-016
TS-1
volasertib
vosaroxin
XL-147
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis.
    To find out more about Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Lung Cancer and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Melanoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Lung Cancer, Melanoma and Pancreatic Cancer. Learn More


Triple Analysis: Colorectal Cancer, Lung Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Lung Cancer and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Melanoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Melanoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Conjugated Drugs in Oncology: Drug Pathway Analyzer
There are today at least 394 conjugated drugs known to affect more than 211 specific intracellular signaling pathways for the treatment of more than 109 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 211 drug targets that are included in this drug-pathway analyzing tool. No less than 190 of these have been recorded with mutations and 36 drug targets have mutations which have been causally implicated in cancer. Learn More